CN Mobile Logo


Anna Azvolinsky, PhD

Anna Azvolinsky, PhD

Freelance science writer and frequent Cancer Network and OncoTherapy Network contributor.

Follow Her on Twitter

Posts by Author

Tracking tumor DNA in the blood of early breast cancer patients following surgery predicted relapse nearly 8 months earlier than conventional imaging.

A complex high-dose combination therapy is tolerable and effective in patients with aggressive B-cell lymphoma that has spread to the central nervous system.

A large study found that while the risk of dying from breast cancer after a DCIS diagnosis is quite low, it is on par with that of women diagnosed with small, invasive breast tumors, and that aggressive DCIS treatment does not produce better results.

Warfarin and a low molecular-weight heparin produced similar results in reducing major blood clots in cancer patients treated for acute venous thromboembolism.

A basket trial of patients with various non-melanoma BRAF-mutated cancers has shown that additional tumor types may also be responsive to vemurafenib.

Testing women for non-BRCA gene mutations that can confer breast or ovarian cancer risk has clinical management consequences for both the women and their family members.

While the risk of a new treatment-related cancer diagnosis after childhood is known, a new study now shows that this risk remains into the fifth and sixth decade of life.

Hypofractionated radiation therapy results in less toxicity and provides a better quality of life compared with conventional whole-breast irradiation, according to two recent studies.

Adding chemotherapy to hormonal therapy in men with metastatic hormone-sensitive prostate cancer increased improved overall survival by 13.6 months.

According to a recent study, the use of oral birth control pills has prevented 200,000 cases of endometrial cancer over the last 10 years.


By clicking Accept, you agree to become a member of the UBM Medica Community.